A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC
This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy, and safety of camrelizumab combined with famitinib malate versus docetaxel as subsequent therapy in Advanced NSCLC.
Advanced NSCLC
DRUG: camrelizumab + famitinib|DRUG: famitinib|DRUG: docetaxel
OS, OS is the time interval from the date of randomization to death due to any reason or lost of follow-up., up to 4 years
PFS, Progression-Free-Survival, defined as the time from randomization to the first occurrence of disease progression with use of RECIST v1.1 or death from any cause, whichever occurs first., up to 4 years|ORR, Objective Response Rate, determined using RECIST v1.1 criteria, defined as best overall response (CR or PR) across all assessment time points., up to 4 years|DoR, Duration of Response, determined using RECIST v1.1 criteria., up to 4 years|DCR, Disease Control Rate, determined using RECIST v1.1 criteria., up to 4 years|TTF, Time to Treatment Failure, defined as the time from randomization to treatment discontinuation., up to 4 years
This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy, and safety of camrelizumab combined with famitinib malate versus docetaxel as subsequent therapy in Advanced NSCLC.